13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013
description
Transcript of 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013
![Page 1: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/1.jpg)
13°International Symposium Heart Failure & Co.
“My sweet Heart”Napoli, 12-13 Aprile 2013
Suscettibilità alla aritmie del miocardio nel diabetico e non: la morte improvvisa
Possible arrhythmic susceptibility of the myocardium in diabetes: the issue of sudden
death.Prof. Luigi Padeletti
Università degli Studi di Firenze
![Page 2: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/2.jpg)
Cardiovascular Mortality In Diabetes Mellitus
Juntilla MJ et al, Heart Rhythm 2010
![Page 3: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/3.jpg)
Cardiovascular Mortality In Diabetes Mellitus
Juntilla MJ et al, Heart Rhythm 2010
![Page 4: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/4.jpg)
Cardiovascular Mortality In Diabetes Mellitus
Juntilla MJ et al, Heart Rhythm 2010
![Page 5: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/5.jpg)
Diabetes Mellitus and Mortality
Cubbon et al, Diabetes & Vascular Disease Research 2013
P < 0.001 P < 0.001
P 0.002
P < 0.001
![Page 6: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/6.jpg)
Diabetes Mellitus & Cardiac Arrest
Jouven X et al, European Heart Journal 2005
![Page 7: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/7.jpg)
Cardiac Damage in Diabetes Mellitus
Adeghate E & Singh J, Heart Failure Reviews 2013
![Page 8: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/8.jpg)
Cardiovascular Autonomic Dysfunction
Pop-Busui R, J of Cardiovsc Trans Res 2012
![Page 9: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/9.jpg)
Cardiovascular Autonomic Dysfunction
Pop-Busui R, J of Cardiovasc Trans Res 2012
![Page 10: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/10.jpg)
![Page 11: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/11.jpg)
![Page 12: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/12.jpg)
La Visione Bidimensionale dell’Appropriatezza
Il concetto di appropriatezza, anche se affonda salde radici nella performance professionale, rappresenta una delle modalità per fronteggiare la cronica carenza di risorse, attraverso una loro ottimizzazione.
![Page 13: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/13.jpg)
2-years total mortality risk
• 20-30 % pts • MUSTT
MADIT IISCD-HeFT
• 20% pts• MADIT II
SCD-HeFT
5-8%
30-50%
![Page 14: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/14.jpg)
ICD benefit as a function of cumulative risk factors
Goldenberg I et al, J Am Coll Cardiol 2008
![Page 15: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/15.jpg)
The MADIT-II Long-Term Risk Score
Barsheshet et al, J Am Coll Cardiol 2012
![Page 16: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/16.jpg)
Predicting Early Mortality in Recipients of ICDs
Kramer D. et al. Heart Rhythm 2012;9:42– 46Kramer DB et al, Heart Rhythm 2012
![Page 17: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/17.jpg)
La razionale applicazione delle indicazioni per l’impianto di ICD e CRT-D evidenzia la necessità di introdurre nella corrente pratica clinica nuove metodiche diagnostiche in grado di identificare il reale rischio aritmico dei pazienti.
![Page 18: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/18.jpg)
What about the neuronal side of the synaptic cleft?
1. In HF cardiac norepinephrine spillover is increased2. In HF pts, cardiac norepinephrine spillover is a powerful
prognostic predictor3. In HF pts, cardiac content of norepinephrine is reduced
Cardiac storage of Norepinephrine is altered in HF
![Page 19: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/19.jpg)
La sinapsi noradrenergica
Lo studio in vivo?
Cao et al., Circulation 2000
![Page 20: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/20.jpg)
Sympathetic preganglionarSimpathetic postganglionar presynapticParasympathetic preganglionar Parasympathetic postganglionar presynaptic Visceral efferentVisceral afferent (sensory)
SNS and HR Sinus nodefunction
Easily interrogated by ECG and HolterLimited relevance in HF progression
SNS and ventricular myocardium
More complex to interrogatePossible role in HF progression
![Page 21: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/21.jpg)
AdreView I123-IobenguanoAdreView is an imaging agent indicated for functional studies of the myocardium (sympathetic innervation)
• AdreView is 123Iodine labeled meta-iodobenzylguanidine (mIBG)• AdreView is an inactive analogue of noradrenaline, with similar uptake &
storage• AdreView scintigraphy helps visualize the noradrenaline uptake & storage, a
measure of sympathetic innervation• AdreView uptake has been shown to be reduced in heart failure• AdreView is therefore a marker of sympathetic damage, a potential
causative factor in lethal arrhythmiasNoradrenaline AdreView
![Page 22: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/22.jpg)
Cardiac sympathetic innervation
H H
Normal Heart failure subject
DHPGDHPG
Monoamine oxidase
80%
20%Normal Noradrenaline
reuptake
Noradrenaline
DHPGDHPG
Monoamine oxidase
<80%
>20%
α1 α1 α1 α1β1β1
β1β1
Noradrenaline
Noradrenaline
Sympathetic nervous terminal
Myocite
Sympathetic nervous terminal
Myocite
Impaired Noradrenaline
reuptake
Noradrenaline
AdreView
AdreView AdreView
AdreView
![Page 23: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/23.jpg)
Healthy subjectNormal EF >60%) H/M ratio: 2.33
Heart failure subjectClass IIIEF = 35%H/M ratio: 1.18
• L'innervazione simpatica cardiaca è misurata dal
Rapporto Cuore/mediastino (H/ M) =quantifica la captazione cardiaca di AdreView
rapporto tra uptake radioattivi: tra la ROI del cuore (H) e la ROI del Mediastino superiore(M), regione senza attività noradrenergica
• il rapporto H / M ha dimostrato di avere un elevato valore prognostico nei pazienti cardiopatici
• Più basso è il rapporto H/M, maggiore è il rischio di morbilità e di mortalità
Morbilità=frequenza di malattia nella popolazione
Mortalità = rapporto tra il numero delle morti in un popolo, durante un periodo di tempo, e la quantità della popolazione media dello stesso periodo.
Normal Diseased
DHPG
DHPG
Monoamine oxidase
80%
20%Normal Noradrenaline
reuptake
Noradrenaline
DHPG
DHPG
Monoamine oxidase
<80%
>20%
H H
MM
α1 α1 α1 α1β1β1 β1
β1
Noradrenaline
Noradrenaline
Sympathetic nervous terminal
Myocite
Sympathetic nervous terminal
Myocite
Impaired Noradrenaline
reuptake
Noradrenaline
AdreView
AdreView AdreView
AdreView
AdreView: come misura l’innervazione simpatica
![Page 24: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/24.jpg)
Danno postischemico
Extent of the MIBG defect correlates with area at risk during acute coronary occlusion. These polar tomograms were obtained from a patient with an acute anterior myocardial infarction. The risk area was quantified with 99mTc-sestamibi prior to reperfusion with percutaneous coronary intervention, and infarct size was documented from repeat imaging 1 week later.31 The defect in sympathetic nerve function assessed with MIBG was significantly larger than the area of infarction and was almost identical to the original extent of myocardial ischemia. Figure source: Dr. Markus Schwaiger. Ant, anterior; Lat, lateral; Inf, inferior; Sep, septum.
Fallavolita J et al, J Nucl Cardiol 2010; 17:1107-15
![Page 25: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/25.jpg)
ADreView Myocardial Imaging for Risk Evaluation
in Heart Failure Study
Jacobson et al., JACC, 2010
AdreView: new evidence from a Heart Failure patient study
![Page 26: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/26.jpg)
Objective
Primary objective• To demonstrate the prognostic value of the H/M ratio of
AdreView for identifying subjects at higher risk of an adverse cardiac event
Secondary objectives• To quantify the risks for adverse cardiac events due to heart
failure and arrhythmias• To assess myocardial sympathetic innervation H/M ratio as
a continuous variable
![Page 27: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/27.jpg)
Adverse cardiac events
Heart failure progression• Progression of heart failure stage from one NYHA class to the other• NYHA II to III or IV – NYHA III to IVLife threatening arrhythmia• Sustained ventricular tachyarrhythmia• Appropriate ICD discharge• Aborted cardiac arrestTerminal cardiac death• Sudden Cardiac Death• Progressive heart failure death• Myocardial Infarction• Cardiac surgery complication
![Page 28: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/28.jpg)
Variable Data RangeMean Age (yr) 62.4 20-90Gender (M/F) (%) 80/20 -Race (White/Black/Other) (%)
75/14/11
-
NYHA II/III (%) 83/17 -HF Etiology (I/NI) (%)I=Ischemic; NI=Non-ischemic
66/34 -
Mean LVEF (%) 27 5-35Median Follow-up (mo) 17 0.1-27ACE Inhibitor*/ARB** (%) 94Beta Blocker (%) 92ARA*** (%) 35 -2-year mortality rate (%) 12.8 -
Patients characteristics
*ACE inhibitors: Angiotensin Converting Enzyme Inhibitors **ARB: Angiotensin Receptor Blockers ***ARA: Aldosterone Receptor Antagonist
![Page 29: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/29.jpg)
The study supports a cut-off value for stratifying the risk of an adverse cardiac eventH/M ratio ≥1.6 – low riskH/M ratio <1.6 – high risk
Finding
![Page 30: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/30.jpg)
237 subjects had an adverse cardiac event on primary analysis
35% greater probability of not experiencing an adverse cardiac event for patients with an H/M ratio ≥1.6 vs. those with H/M ratio <1.6
Kaplan-Meier estimates of ACE free probability18
H/M ratioAC
E fr
ee p
roba
bilit
y (%
)
Time (months)
*p=0.0001 vs H/M ratio≥1.60
H/M ratio ≥1.60; ACE free probability = 85%
22 %35%
201 subject 25 events
760 subjects212 events
H/M ratio <1.60; ACE free probability = 63%
Separation from groups is evident within the first two months
![Page 31: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/31.jpg)
Greater arrhythmia-free survival at 2 years for patients with H/M ratio ≥1.6 vs. those with H/M ratio of <1.6
Estimates of arrhythmia free probability H/M ratio
64 patients had an arrhythmia on secondary analysis
Arrh
ythm
ia fr
ee
prob
abili
ty (
%)
*p=0.002 vs H/M ratio≥1.60
H/M ratio<1.60: 2-year event-free survival 85%*
H/M ratio≥1.60: 2-year event-free survival 96%
201 subjects6 arrhythmias
760 subjects 58 arrhythmias
Negative Predictive Value of arrhythmia likelihood is 96% NPV 96% for arrhythmias21
Time (months)
![Page 32: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/32.jpg)
Kaplan-Meier estimates of ACE incidence LVEF
LVEF 30% MADIT II threshold on ACEAC
E Cu
mul
ativ
e in
cide
nce
(%)
Months
LVEF<30%
LVEF≥30%
0
10
20
30
40p<0.0001
50
0 6 12 18 24
471 subjects 83 events
490 subjects 154 events
![Page 33: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/33.jpg)
H/M ratio 1.6 ADMIRE-HF threshold vs. LVEF 30% MADIT II threshold on ACE
ACE
Cum
ulat
ive
inci
denc
e (%
)
Months
LVEF<30%, H/M<1.60*
LVEF<30%, H/M≥1.60*
0
10
20
30
40 *p=0.0004†p=0.024
50
LVEF≥30%, H/M≥1.60†
LVEF≥30%, H/M<1.60†
H/M ratio 1.6 threshold provides additional information over EF 30% threshold
ACE incidence H/M ratio vs. LVEF
0 6 12 18 24
120 subjects 13 events
351 subjects 70 events
81 subjects 12 events
409 subjects 142 events
![Page 34: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/34.jpg)
Correlazione tra morte cardiaca e il rapporto cuore/mediastino (H/M) alla scintigrafia con MIBG con acquisizione tardiva in pazienti con insufficienza cardiaca.
Jacobson AF et al, J Am Coll Cardiol 2010
![Page 35: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/35.jpg)
Boogers MJ et al, J Am Coll Cardiol 2010
Difference in appropriate ICD therapy between patients with a large or small 123-I MIBG SPECT
![Page 36: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/36.jpg)
Shah et al, JACC: Cardiovascular Imaging 2012
Incidence of Death and Arrhythmic Events according to LVEF & Heart/Mediastinum Ratio
![Page 37: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/37.jpg)
DIABETIC PATIENTS: PROGRESSION TO HF
Gerson MC et al, Circ Cardiovasc Imaging 2011
![Page 38: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/38.jpg)
![Page 39: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/39.jpg)
Il Ruolo delle Società Scientifiche
Affidarsi ai principi dell’Appropriatezza, richiede una duplice revisione di posizioni, spesso estreme e conflittuali:
1. i professionisti, non devono inquadrare il principio dell’appropriatezza nella strategia dei tagli incondizionati
2. i decisori, accettando che perseguire l’appropriatezza non serve a ridurre i costi, ma solo ad ottimizzare l’impiego delle risorse, devono “mettere a fuoco” la dimensione dell’inappropriatezza in difetto, per non rischiare di rallentare la diffusione delle innovazioni di provata efficacia.
![Page 40: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/40.jpg)
Il Ruolo delle Società Scientifiche
• Per attuare tale meccanismo virtuoso di valutazione occorre che le società scientifiche siano attori proattivi nell’iter di valutazione delle innovazioni tecnologiche e dei percorsi.
• Valutazioni “ad hoc” condivise con tutti i diversi portatori di interesse.
![Page 41: 13°International Symposium Heart Failure & Co. “ My sweet Heart ” Napoli, 12-13 Aprile 2013](https://reader036.fdocuments.in/reader036/viewer/2022081520/5681655e550346895dd7e194/html5/thumbnails/41.jpg)
European Journal of Public Health 2011